Drug intelligence / Profile preview

(R)-fluoxetine

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

(R)-Fluoxetine is the R-enantiomer of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Fluoxetine is used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, bulimia nervosa, and premenstrual dysphoric disorder. The drug works by inhibiting the presynaptic reuptake of serotonin in the brain through high affinity for serotonin transporters (5-HT transporters), thereby increasing synaptic levels of serotonin and improving mood and anxiety symptoms. Fluoxetine was originally developed by Eli Lilly and has been marketed under several brand names including Prozac and Sarafem[1][2][4][5][6][8].

Other names: (R)-fluoxetine

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on (R)-fluoxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (R)-fluoxetine.

Explore the full profile